The Clinical Significance of Erythrocytic Macrocytosis in Metastatic Renal Cell Cancer and Sarcoma Patients Treated with Pazopanib

Authors : Yusuf Ilhan, Mehmet Fatih Özbay, Sema Sezgin Göksu, Ali Murat Tatli, Hasan Şenol Coşkun

Pages : 131-136

Doi:10.53394/akd.1174869

View : 27 | Download : 43

Publication Date : 2024-01-01

Article Type : Research Paper

Abstract :Objective: Pazopanib is a multi-kinase inhibitor used in metastatic renal cell carcinoma or sarcomas (mRCC or mSTS). We aimed to investigate the relationship between pazopanib and macrocytosis and evaluate the clinical significant of this effect in mRCC or mSTS. Methods: Patients diagnosed with mRCC and mSTS and have been treated with pazopanib were included. Drug-induced macrocytosis was defined as MCV >100 fL during any mount of treatment. ΔMCV was defined as difference between MCV during pazopanib treatment and baseline MCV. Data was collected retrospectively. Results: 50 patients were included the study. During the pazopanib treatment, significant increase in MCV levels was observed and the mean MCV at the 0, 1, 3, 6, and 9 months were found as 86.7±7.6 fL, 87.8 ± 7.5, 92.4 ± 8.9, 94.8 ± 11.1 and 99.0 ± 10.7 fL, retrospectively (p<0.001). In the group with ΔMCV3 ≥ 5fL, median PFS was found 48.0 months (95% CI, 26.3-69.9); in the group with ΔMCV3 <5, it was 25 months (95% CI, 14.6-35.4) (p:0.036). Median PFS was 21.0 months (%95 CI, 0-46.3) for macrocytic patients compared to 4.0 months (%95 CI, 2.0-5.9) in normocytic patients (p:0.023).There was no statistically significant difference between the groups for overall survival. Conclusion: A significant increases in MCV values or the development of macrocytosis during the pazopanib treatment in mRCC and mSTS, can be used as an important biomarker for progression-free survival.
Keywords : Ortalama eritrosit hacmi MCV, Makrositoz, Pazopanib, Progresyonsuz Sağkalım